The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.

ABSTRACT:

Background

Body composition is an important predictor of drug toxicity and outcome. Ipilimumab (Ipi), a monoclonal antibody used to treat metastatic melanoma, has specific toxicities. No validated biomarkers that predict Ipi toxicity and efficacy exist. Also, the impact of Ipi on body composition has not been established.

Methods

Patients with metastatic melanoma treated with Ipi between 2009 and 2015 were included. Body composition was assessed by computed tomography at baseline and after four cycles of Ipi. Sarcopenia and low muscle attenuation (MA) were defined using published cut-points. All adverse events (AEs) and immune-related AEs (irAEs) were recorded (Common Terminology Criteria For Adverse Event V.4.0).

Results

Eighty-four patients were included in this stu

SUBMITTER: Daly LE 

PROVIDER: S-EPMC5294486 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature